Research programme: Parkinson's disease therapeutics - MIGENIX/Pfizer

Drug Profile

Research programme: Parkinson's disease therapeutics - MIGENIX/Pfizer

Latest Information Update: 30 Jan 2008

Price : $50

At a glance

  • Originator MIGENIX
  • Developer MIGENIX; Pfizer
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 30 Jan 2008 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route)
  • 15 Jun 2007 No development reported - Preclinical for Parkinson's disease in USA (unspecified route)
  • 23 Sep 2004 Micrologix Biotech is now called MIGENIX
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top